RESUMO
BACKGROUND: Few studies have examined health related Quality of Life (HR-QoL) during the treatment of head and neck cancer (HNC) with even fewer focusing on the impact of oral mucositis (OM) on HR-QoL. Studies performed during treatment of HNC makes it possible to follow fluctuations in HR-QoL, OM and other treatment related side effects. The aim was to prospectively analyze HR-QoL, changes in clinical variables and the impact of OM on HR-QoL during HNC treatment. MATERIALS AND METHODS: Patients were recruited before commencing curative cancer treatment and were given professional oral care weekly during oncologic treatment. HR-QoL was reported before, during (week 2, 4 and 6) and three months after treatment using the EORTC Quality of Life questionnaires C30 and H&N35 and the stimulated whole salivary secretion rate was determined at the same time-points. OM (erythema and ulceration) was registered using the Oral Mucositis Assessment Scale (OMAS), at baseline, weekly during treatment and post treatment. Differences in HR-QoL between different timepoints were analyzed. To analyze the impact of OM on HR-QoL the patients were categorized into two groups: no/mild OM (OMAS ulceration score 0-1) or severe OM (OMAS ulceration score ≥ 2) and HR-QoL was compared between the two OM groups at three timepoints during treatment. RESULTS: Fifty-seven patients (43 men, 14 women), with a mean age of 58 years were included. Patients reported progressively impaired HR-QoL, with peak issues noted at weeks 4 and 6, particularly in social eating, senses, appetite loss, sticky saliva, and decreasing salivary secretion rates were determined. Patients with severe OM reported worse HR-QoL compared to those with no/mild OM. Persistent problems 3 months post treatment were appetite loss, dry mouth, senses (smell and taste) and problems with social eating. CONCLUSION: Patients experienced exacerbated symptoms and problems weeks 4 and 6 of oncological treatment, especially among those with severe OM, stressing the importance of clinically monitoring the patients to reduce and alleviate their symptoms. Persistent problems three months post treatment are likely associated with the reduced salivary secretion rate indicating that patients should be monitored also after completed oncological treatment.
Assuntos
Neoplasias de Cabeça e Pescoço , Saúde Bucal , Qualidade de Vida , Estomatite , Humanos , Estomatite/etiologia , Estomatite/psicologia , Estudos Prospectivos , Masculino , Feminino , Pessoa de Meia-Idade , Neoplasias de Cabeça e Pescoço/psicologia , Neoplasias de Cabeça e Pescoço/complicações , Neoplasias de Cabeça e Pescoço/terapia , Idoso , Adulto , Xerostomia/psicologia , Xerostomia/etiologia , Seguimentos , Saliva/metabolismo , Saliva/química , Salivação/efeitos dos fármacos , Inquéritos e QuestionáriosRESUMO
OBJECTIVE: To investigate the mechanism of cAMP-PKA signaling pathway mediated by Chinese medicine formula Shaoyao Gancao Decoction (, SGD) on the regulation of aquaporin 5 (AQP5) and muscarinic receptor 3 (M3R) levels in Sjögren's syndrome (SS). METHODS: Of the 30 mice, 5 were randomly selected as control, and others were used for creating SS model. After successful modeling, mice were randomly divided into 5 groups (n=5 per group) and intragastrically administered with saline (8 mL/kg), pilocarpine (1.4 mg/kg), or low, medium and high doses SGD (0.14, 0.21, 0.35 g/kg Radix paeoniae with 0.01 g/kg Radix glycyrrhizae, respectively) for 6 weeks. Human labial gland acinar cells were treated with pilocarpine or varying doses of SGD with saline as the placebo. Hematoxylin and eosin staining was used to observe the histopathological changes of the submandibular glands of mice. The serum levels of anti-SS antigen A (SS-A), anti-SS antigen B (SS-B), M3R, and α-fodrin in submandibular glands of mice were measured by enzyme-linked immunosorbent assay. Immunofluorescence staining was used to observe the spatial localization of AQP5 and M3R in acinar cells. Reverse transcriptase polymerase chain reaction and Western blot were used to detect the expressions of PKA, cAMP, Epac1, AQP5, M3R, nuclear factor kappa-B (NF-κB), and tumor necrosis factor (TNF)-α in submandibular gland tissues and cells of each group. RESULTS: Compared to normal mice, body weight, 5-min salivary secretion, 30-min secretion of tears and breakup time of tear film of model mice decreased at 1-6 weeks after immunization (all P<0.05), whereas water intake increased (all P<0.05). In the model group, glands of the submandibular glands showed atrophy, accompanied by acini of different sizes, decreased numbers and loose arrangement, with catheter dilatation and different degrees of lymphocyte infiltration. Conditions of mice in SGD groups were improved. The positive expression of AQP5 and M3R were higher in the acinar cells treated with all doses SGD compared to the normal group; serum levels of SS-A, SS-B, and α-fodrin were lower, and that of M3R was higher in all doses SGD treated animals than the model or pilocarpine treated ones (all P<0.05). Compared to the model and pilocarpine groups, the mRNA and protein levels of NF-κB and TNF-α were lower in mice or cells treated with medium or high-dose SGD (all P<0.05), while those of PKA, Epac1, AQP5 and M3R were higher (all P<0.05). CONCLUSION: SGD can improve symptoms of SS by regulating the cAMP-PKA signaling pathway and increasing AQP5 and M3R levels.
Assuntos
Aquaporina 5/metabolismo , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Receptor Muscarínico M3/metabolismo , Síndrome de Sjogren/tratamento farmacológico , Células Acinares , Animais , Modelos Animais de Doenças , Feminino , Humanos , Camundongos , Paeonia , Salivação/efeitos dos fármacos , Glândula Submandibular/efeitos dos fármacosRESUMO
Xerostomia e/ou hipossalivação é uma das mais frequentes complicações orais em pacientes irradiados em região de cabeça e pescoço, com importante impacto na qualidade de vida ao longo do tempo. O objetivo do estudo, foi avaliar a eficácia do Bioxtra Spray® na redução da intensidade de xerostomia e seu impacto na qualidade de vida em pacientes que foram irradiados em região de cabeça e pescoço pela técnica de Radioterapia de Intensidade Modulada (IMRT) ou Radioterapia Conformada Tridimensional (RTC3D), em um período de 8 a 9 meses após o término do tratamento. Foi realizado um estudo prospectivo, randomizado, duplo cego e placebo controlado, com um total de 40 pacientes alocados no Grupo Placebo (n=19) ou Bioxtra Spray® (n=21). Os pacientes utilizaram ambos os produtos três vezes ao dia durante 30 dias. Para as análises, foram realizadas a avaliação da intensidade da xerostomia, avaliação da taxa de fluxo salivar não estimulada e estimulada através da sialometria e a avaliação da qualidade de vida através do Questionário de Qualidade de Vida da Universidade de Washington, validado em português (QQV-UW) em 2 fases: Fase 1 (antes do uso de ambos os produtos); Fase 2 (após 30 dias de uso dos produtos). Em relação à intensidade da xerostomia, não foram observadas melhoras significativas da queixa de boca seca após 30 dias de uso do Bioxtra Spray®( p>0,05). Analisando os exames de sialometria, foi observado que, após 30 dias de uso, o Grupo Bioxtra Spray® apresentou saliva não estimulada e estimulada significativamente maior quando comparado ao Grupo Placebo (p<0,05). Em relação à qualidade de vida, de maneira geral o Grupo Placebo apresentou melhores escores gerais dos domínios do QQV-UW quando comparados ao Grupo Bioxtra Spray® nas duas fases do estudo (p<0,05). Não foram observadas diferenças significativas em relação ao domínio saliva do QQV-UW entre os grupos nas duas fases do estudo. Interessante observar que os pacientes de ambos os Grupos que foram submetidos à técnica IMRT apresentaram índices tanto na taxa de fluxo salivar quanto na qualidade de vida significativamente melhores em ambas as fases do estudo quando comparados à técnica RTC3D. Por fim, concluímos que o Bioxtra Spray®, na metodologia estudada, não apresentou resultados positivos na lubrificação oral e na qualidade de vida dos pacientes. Contudo, estudos em longo prazo que avaliam seu efeito enzimático na proteção dos tecidos orais são recomendados
Xerostomia and/or hyposalivation are common oral complication in patients irradiated in the head and neck region with an important impact on quality of life over time. The aim of this study was to evaluate the effectiveness of Bioxtra Spray® in reducing xerostomia intensity and its impact on the quality of life of patients who were irradiated in the head and neck region by the Intensity Modulated Radiation Therapy (IMRT) or Three Dimensional Conformal Radiotherapy (RTC3D) over a period of 6 months to 1 year after the end of treatment. A prospective, randomized, double-blind, placebo-controlled study was performed, with a total of 40 patients allocated to the Placebo Arm (n= 19) or Bioxtra Spray® (n = 21). Patients used both products three times a day for 30 days and for the analyzes, the evaluation of xerostomia grade, evaluation of the unstimulated and stimulated salivary flow rate through sialometry and the evaluation of quality of life through the University of Washington Quality of Life Questionnaire, validated in Portuguese (UW-QoL) were performed in 2 phases: Phase 1 (before the use of both products); Phase 2 (after 30 days of using both products). Regarding xerostomia grade, no significant improvement in dry mouth complaints was observed after 30 days of use (p> 0.05). Analyzing the sialometry exams, it was observed that after 30 days of use, the Bioxtra Spray® Group showed unstimulated and stimulated salivary flow rate significantly higher when compared to the Placebo Arm (p <0.05). Regarding quality of life, in general, the Placebo Arm had better overall scores than in the UW-QoL domains when compared to the Bioxtra Spray® Group in the two phases of the study (p <0.05). No significant differences were observed in relation to the UW-QoL saliva domain between the groups in the two phases of the study. It is interesting to note that patients from both Groups who underwent the IMRT technique showed significantly better rates of salivary flow and quality of life in both phases of the study when compared to the RTC3D technique. In conclusion, we observed that Bioxtra Spray® did not present positive results in oral lubrication and in patients' quality of life. However, studies evaluating its enzymatic effect in protecting oral tissues are recommended
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Saliva Artificial/uso terapêutico , Xerostomia/etiologia , Xerostomia/tratamento farmacológico , Neoplasias Faríngeas/radioterapia , Radioterapia Conformacional/efeitos adversos , Carcinoma de Células Escamosas de Cabeça e Pescoço/radioterapia , Placebos , Qualidade de Vida , Saliva Artificial/farmacologia , Salivação/efeitos dos fármacos , Neoplasias Orofaríngeas/radioterapia , Neoplasias Nasofaríngeas/radioterapia , Método Duplo-Cego , Estudos Prospectivos , Radioterapia de Intensidade Modulada/efeitos adversos , Sprays OraisRESUMO
The most important salivary glands are the paired parotid and submandibular glands. Adults produce 1 to 1.5 liters of saliva which are then regularly swallowed. When the act of swallowing is disturbed, salivation occurs. More rarely, the cause can be found in increased saliva production, for example, when caused through medication. Sialorrhea impairs the quality of life substantially and is frequently often socially stigmatizing. Therapy includes conservative measures such as functional dysphagia therapy, oral or transdermal application of anticholinergics, as well as, in selected cases, radiation and surgical measures. Over the last 20 years local injection of botulinum toxin has been successfully applied in the treatment of this condition. With approval of this therapy by the European agencies, this measure will become the therapy of choice for pronounced therapy-resistant sialorrhea.
Assuntos
Toxinas Botulínicas/uso terapêutico , Sialorreia/terapia , Adulto , Humanos , Qualidade de Vida , Glândulas Salivares/efeitos dos fármacos , Glândulas Salivares/metabolismo , Salivação/efeitos dos fármacos , Sialorreia/tratamento farmacológicoRESUMO
Head and neck cancer treatments typically involve a combination of surgery and radiotherapy, often leading to collateral damage to nearby tissues causing unwanted side effects. Radiation damage to salivary glands frequently leads to irreversible dysfunction by poorly understood mechanisms. The P2X7 receptor (P2X7R) is a ligand-gated ion channel activated by extracellular ATP released from damaged cells as "danger signals." P2X7R activation initiates apoptosis and is involved in numerous inflammatory disorders. In this study, we utilized P2X7R knockout (P2X7R-/-) mice to determine the role of the receptor in radiation-induced salivary gland damage. Results indicate a dose-dependent increase in γ-radiation-induced ATP release from primary parotid gland cells of wild-type but not P2X7R-/- mice. Despite these differences, apoptosis levels are similar in parotid glands of wild-type and P2X7R-/- mice 24-72 h after radiation. However, γ-radiation caused elevated prostaglandin E2 (PGE2) release from primary parotid cells of wild-type but not P2X7R-/- mice. To attempt to uncover the mechanism underlying differential PGE2 release, we evaluated the expression and activities of cyclooxygenase and PGE synthase isoforms. There were no consistent trends in these mediators following radiation that could explain the reduction in PGE2 release in P2X7R-/- mice. Irradiated P2X7R-/- mice have stimulated salivary flow rates similar to unirradiated controls, whereas irradiated wild-type mice have significantly decreased salivary flow rates compared with unirradiated controls. Notably, treatment with the P2X7R antagonist A438079 preserves stimulated salivary flow rates in wild-type mice following γ-radiation. These data suggest that P2X7R antagonism is a promising approach for preventing γ-radiation-induced hyposalivation.
Assuntos
Raios gama , Glândula Parótida/metabolismo , Lesões por Radiação/prevenção & controle , Receptores Purinérgicos P2X7/deficiência , Salivação , Xerostomia/prevenção & controle , Trifosfato de Adenosina/metabolismo , Animais , Apoptose , Dinoprostona/metabolismo , Modelos Animais de Doenças , Feminino , Deleção de Genes , Camundongos Endogâmicos C57BL , Camundongos Knockout , Glândula Parótida/efeitos dos fármacos , Glândula Parótida/fisiopatologia , Prostaglandina-E Sintases/metabolismo , Prostaglandina-Endoperóxido Sintases/metabolismo , Antagonistas do Receptor Purinérgico P2X/farmacologia , Lesões por Radiação/genética , Lesões por Radiação/metabolismo , Lesões por Radiação/fisiopatologia , Receptores Purinérgicos P2X7/efeitos dos fármacos , Receptores Purinérgicos P2X7/genética , Salivação/efeitos dos fármacos , Xerostomia/genética , Xerostomia/metabolismo , Xerostomia/fisiopatologiaRESUMO
GPR55, a lipid-sensing receptor, is implicated in cell cycle control, malignant cell mobilization, and tissue invasion in cancer. However, a physiological role for GPR55 is virtually unknown for any tissue type. Here, we localize GPR55 to self-renewing ductal epithelial cells and their terminally differentiated progeny in both human and mouse salivary glands. Moreover, we find GPR55 expression downregulated in salivary gland mucoepidermoid carcinomas and GPR55 reinstatement by antitumor irradiation, suggesting that GPR55 controls renegade proliferation. Indeed, GPR55 antagonism increases cell proliferation and function determination in quasiphysiological systems. In addition, Gpr55-/- mice present ~50% enlarged submandibular glands with many more granulated ducts, as well as disordered endoplasmic reticuli and with glycoprotein content. Next, we hypothesized that GPR55 could also modulate salivation and glycoprotein content by entraining differentiated excretory progeny. Accordingly, GPR55 activation facilitated glycoprotein release by itself, inducing low-amplitude Ca2+ oscillations, as well as enhancing acetylcholine-induced Ca2+ responses. Topical application of GPR55 agonists, which are ineffective in Gpr55-/- mice, into adult rodent submandibular glands increased salivation and saliva glycoprotein content. Overall, we propose that GPR55 signaling in epithelial cells ensures both the life-long renewal of ductal cells and the continuous availability of saliva and glycoproteins for oral health and food intake.
Assuntos
Células-Tronco Adultas/fisiologia , Carcinoma Mucoepidermoide/patologia , Diferenciação Celular/fisiologia , Receptores de Canabinoides/metabolismo , Neoplasias das Glândulas Salivares/patologia , Salivação/fisiologia , Adulto , Células-Tronco Adultas/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Animais , Agonistas de Receptores de Canabinoides/farmacologia , Antagonistas de Receptores de Canabinoides/farmacologia , Carcinoma Mucoepidermoide/radioterapia , Diferenciação Celular/efeitos dos fármacos , Autorrenovação Celular/efeitos dos fármacos , Autorrenovação Celular/fisiologia , Regulação para Baixo , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Feminino , Glicoproteínas/metabolismo , Humanos , Masculino , Camundongos , Camundongos Knockout , Pessoa de Meia-Idade , Receptores de Canabinoides/genética , Saliva/química , Saliva/metabolismo , Neoplasias das Glândulas Salivares/radioterapia , Salivação/efeitos dos fármacos , Glândula Submandibular/efeitos dos fármacos , Glândula Submandibular/metabolismo , Glândula Submandibular/patologiaRESUMO
Sichuan pepper is a plant belonging to the genus Zanthoxylum and family rue. To evaluate whether Sichuan pepper oil boosts saliva secretion using an encapsulated food product containing the oil in subjects presenting with mouth dryness. We evaluated subjective symptoms that changed with a decrease in salivary secretion in the subjects by evaluating the number of Candida colonies and by conducting interviews. The study results demonstrated that salivary secretion increased by 39.4% ± 37.6% after single ingestion of the product, and an additional 8.7% ± 13.2% and 6.3% ± 31.2% following continuous ingestion over 2 and 4 weeks, respectively. These findings suggested that the product rapidly promotes and maintains salivation. Regarding the proliferation of Candida colonies in subjects with mouth dryness, a negative correlation was observed between Candida colony number and salivary secretion quantity. Additionally, interviews revealed that subjective symptoms, such as mouth dryness, discomfort and pain in the mouth, difficulty swallowing the saliva, and feeling of stickiness in the mouth, improved shortly after single ingestion of the product, and mouth dryness was reduced by continuous consumption of the product. These findings indicated that the product studied promotes rapid salivary secretion, is effective in reducing the number of oral Candida colonies, and improves subjective symptoms such as mouth dryness.
Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Fitoterapia , Salivação/efeitos dos fármacos , Xerostomia/tratamento farmacológico , Zanthoxylum , Adulto , Idoso , Idoso de 80 Anos ou mais , Candida/isolamento & purificação , Deglutição/efeitos dos fármacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Boca/efeitos dos fármacos , Boca/microbiologia , Óleos de Plantas/uso terapêutico , Saliva/efeitos dos fármacos , Inquéritos e Questionários , Xerostomia/microbiologia , Adulto JovemRESUMO
BACKGROUND: Allotransplantation of submandibular salivary glands (SMGs) could be an alternative treatment option for severe keratoconjunctivitis sicca in noncandidates for autologous SMG transplantation. This study was conducted to evaluate the effect of allogeneic mesenchymal stem cell (MSC) therapy on the survival of allotransplanted SMGs. METHODS: Thirty-six SMG allotransplantations (n = 6 per group) were performed in New Zealand white rabbits and randomly divided into the following groups: allograft control (Allo-Ctrl), low-dose FK506 (FK506-L), high-dose FK506 (FK506-H), allogeneic MSCs, MSCs+FK506-L, and MSCs+FK506-H. Rabbits were closely observed for 2 weeks. Gland viability and rejection were assessed by monitoring interleukin-2 levels by ELISA, sialoscintigraphy, M3-muscarinic acetylcholine receptor expression, histological evaluation, and apoptosis assay. RESULTS: Intraoperatively, all glands showed patency and saliva flow except 1 gland. Sialoscintigraphy revealed significantly higher saliva production within the MSC-treated glands. Histologically, MSC-treated glands showed higher glandular tissue preservation and less acini atrophy. The MSCs+FK506-H group revealed significantly lower apoptosis percentage. The highest survival was observed in the MSCs+FK506-H group, followed by the FK506-H and MSCs+FK506-L groups, and lastly less in the FK506-L and MSCs groups. CONCLUSIONS: Concurrent administration of MSCs with FK506-H (0.16 mg/kg) resulted in higher survival rate with greater glandular tissue preservation and salivary secretion. MSCs with FK506-L (0.08 mg/kg) could be an alternative to FK506-H (0.16 mg/kg) in salivary gland allotransplantation.
Assuntos
Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto/efeitos dos fármacos , Imunossupressores/administração & dosagem , Transplante de Células-Tronco Mesenquimais , Glândula Submandibular/efeitos dos fármacos , Glândula Submandibular/transplante , Tacrolimo/administração & dosagem , Células Alógenas/imunologia , Células Alógenas/metabolismo , Células Alógenas/patologia , Animais , Apoptose/efeitos dos fármacos , Atrofia , Feminino , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/metabolismo , Rejeição de Enxerto/patologia , Interleucina-2/metabolismo , Masculino , Coelhos , Receptor Muscarínico M3/metabolismo , Salivação/efeitos dos fármacos , Glândula Submandibular/imunologia , Glândula Submandibular/patologia , Fatores de Tempo , Sobrevivência de Tecidos/efeitos dos fármacos , Transplante HomólogoRESUMO
Importance: Whole-brain radiation therapy (WBRT) delivers a substantial radiation dose to the parotid glands, but the parotid glands are not delineated for avoidance and xerostomia has never been reported as an adverse effect. Minimizing the toxic effects in patients receiving palliative treatments, such as WBRT, is crucial. Objective: To assess whether xerostomia is a toxic effect of WBRT. Design, Setting, and Participants: This observational cohort study enrolled patients from November 2, 2015, to March 20, 2018, at 1 academic center (University of North Carolina Hospitals) and 2 affiliated community hospitals (High Point Regional Hospital and University of North Carolina Rex Hospital). Adult patients (n = 100) receiving WBRT for the treatment or prophylaxis of brain metastases were enrolled. Patients who had substantial baseline xerostomia or did not complete WBRT or at least 1 postbaseline questionnaire were prospectively excluded from analysis and follow-up. Patients received 3-dimensional WBRT using opposed lateral fields covering the skull and the C1 or C2 vertebra. Per standard practice, the parotid glands were not prospectively delineated. Main Outcomes and Measures: Patients completed the University of Michigan Xerostomia Questionnaire and a 4-point bother score at baseline, immediately after WBRT, at 1 month, at 3 months, and at 6 months. The primary end point was the 1-month xerostomia score, with a hypothesized worsening score of 10 points from baseline. Results: Of the 100 patients enrolled, 73 (73%) were eligible for analysis and 55 (55%) were evaluable at 1 month. The 73 patients included 43 women (59%) and 30 men (41%) with a median (range) age of 61 (23-88) years. The median volume of parotid receiving at least 20 Gy (V20Gy) was 47%. The mean xerostomia score was 7 points at baseline and was statistically significantly higher at each assessment period, including 21 points immediately after WBRT (95% CI, 16-26; P < .001), 23 points (95% CI, 16-30; P < .001) at 1 month, 21 points (95% CI, 13-28; P < .001) at 3 months, and 14 points (95% CI, 7-21; P = .03) at 6 months. At 1 month, the xerostomia score increased by 20 points or more in 19 patients (35%). The xerostomia score at 1 month was associated with parotid dose as a continuous variable and was 35 points in patients with parotid V20Gy of 47% or greater, compared with only 9 points in patients with parotid V20Gy less than 47% (P < .001). The proportion of patients who self-reported to be bothered quite a bit or bothered very much by xerostomia at 1 month was 50% in those with parotid V20Gy of 47% or greater, compared with only 4% in those with parotid V20Gy less than 47% (P < .001). At 3 months, this difference was 50% vs 0% (P = .001). Xerostomia was not associated with medication use. Conclusions and Relevance: Clinically significant xerostomia occurred by the end of WBRT, appeared to be persistent, and appeared to be associated with parotid dose. The findings from this study suggest that the parotid glands should be delineated for avoidance to minimize these toxic effects in patients who undergo WBRT and often do not survive long enough for salivary recovery.
Assuntos
Neoplasias Encefálicas/radioterapia , Irradiação Craniana/efeitos adversos , Órgãos em Risco , Glândula Parótida/efeitos da radiação , Doses de Radiação , Lesões por Radiação/etiologia , Radioterapia Conformacional/efeitos adversos , Salivação/efeitos dos fármacos , Xerostomia/etiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias Encefálicas/secundário , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , North Carolina , Glândula Parótida/fisiopatologia , Estudos Prospectivos , Lesões por Radiação/diagnóstico , Lesões por Radiação/fisiopatologia , Medição de Risco , Fatores de Risco , Fatores de Tempo , Xerostomia/diagnóstico , Xerostomia/fisiopatologia , Adulto JovemRESUMO
OBJECTIVE: To investigate the protective effect of Zengye Decoction (, ZYD) on the submandibular glands (SMGs) in nonobese diabetic (NOD) mice. METHODS: Twenty-seven female NOD mice were randomly equally divided into 3 groups: the model group, the hydroxychloroquine (HCQ) group, and the ZYD group. Nine C57/B6 mice served as the normal group. After 1-week acclimation, the HCQ and ZYD groups were intragastrically administered with HCQ and ZYD, respectively, and the normal and model groups were administered with normal saline. Changes in the salivary flow rate were observed. Mice from all 4 groups were sacrificed at the age of 20 weeks. The serum and SMGs were collected. Serum cytokines gamma-interferon (IFN-γ), interleukin-10 (IL-10) were detected by enzyme-linked immunosorbent assay. Histological changes in the submandibular glands were examined by hematoxylin and eosin staining. The mRNA expression of IFN-γ, IL-10 and vasoactive intestinal peptide (VIP) in the submandibular glands were measured by real-time polymerase chain reaction. RESULTS: Compared with the model group, the salivary flow of the ZYD group significantly increased (P<0.05), the extent of the histological changes was ameliorated (P<0.05), and the Th1/Th2 cytokine imbalance was remedied (P<0.05). In the ZYD-treated mice, the VIP mRNA was up-regulated (P<0.05). CONCLUSIONS: ZYD is beneficial in protecting structure and function of SMGs in NOD mice. The mechanism may be associated with the correction of the Th1/Th2 cytokine imbalance, and with the prevention of a progressive decline of the VIP level.
Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Síndrome de Sjogren/tratamento farmacológico , Glândula Submandibular/efeitos dos fármacos , Animais , Citocinas/sangue , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos NOD , Salivação/efeitos dos fármacos , Síndrome de Sjogren/imunologia , Glândula Submandibular/patologia , Células Th1/imunologia , Células Th2/imunologia , Peptídeo Intestinal Vasoativo/genéticaRESUMO
OBJECTIVES: To analyze the role of patient compliance as a factor in evaluating the effectiveness of continuous sialogogues to prevent salivary side effects from 131 I therapy in differentiated thyroid cancer patients. METHODS: Differentiated thyroid cancer patients who were clinically scheduled for an 131 I therapy at MedStar Washington Hospital Center between 2012 and 2013 were given instructions for continuous sialogogues per standard clinical protocol. The prospective survey was given at multiple time points. RESULTS: Ninety-nine patients consented to participate of whom 94 participants had complete data. The mean prescribed 131 I activity was 121 ± 50 mCi (4.5 ± 1.9 GBq), range 27.5-288 mCi (1.0-10.7 GBq ). Overall, only 10% (9/94) of patients were compliant with continuous sialogogues. Even though all patients took sialogogues on the first day of post-therapy, 17% of participants did not continuously take sialogogues during the first day, 60% during the first night, and 72% on the second day despite rigorous instructions to continue for two days. CONCLUSION: Despite repetitive instructions to use sialogogues continuously, most patients (90%) were not compliant. In future studies, strict monitoring and evaluation of patient compliance will be crucial when assessing the effect of continuous versus intermittent or delayed initiation of sialogogues.
Assuntos
Adesão à Medicação , Salivação/efeitos dos fármacos , Sialadenite/tratamento farmacológico , Neoplasias da Glândula Tireoide/radioterapia , Xerostomia/tratamento farmacológico , Adulto , Idoso , Feminino , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sialadenite/etiologia , Inquéritos e Questionários , Neoplasias da Glândula Tireoide/complicações , Xerostomia/etiologiaRESUMO
OBJECTIVES: Medication-induced hyposalivation can increase the risk for oral complications, including dental caries and tooth loss. This problem is particularly important in people with dementia because of their declining ability to maintain oral care. The objective of this study was to describe the association between the number of xerostomic medications used and tooth loss and restorative and dental preventive treatment in a population of persons with dementia. DESIGN: A longitudinal population-based register study with a 3-year follow-up was conducted. Data were extracted from the Swedish Dementia Registry (SveDem), the Swedish Prescribed Drug Register (SPDR), the Swedish National Patient Register (SNPR), and the Dental Health Register (DHR). SETTING AND PARTICIPANTS: Participants were persons with dementia who were registered in the SveDem at the time of their dementia diagnosis. MEASURES: The exposure was continuous use of xerostomic medications over the 3 years prior to dementia diagnosis (baseline). The outcomes were the incidence of tooth extractions, tooth restorations, and dental preventive procedures. Poisson regression models were used to estimate incidence rate ratios (IRRs) for the association between the exposure and outcomes, adjusting for relevant confounders. RESULTS: A total of 34,037 persons were included in the analysis. A dose-response relationship between the exposure and tooth extractions was observed. Compared with nonusers of xerostomic medication, the rate of tooth extractions increased with increasing number of xerostomic medications used (IRR = 1.03, 1.11, and 1.40 for persons using an average >0-1, >1-3, and >3 xerostomic medications, respectively). However, the risk for having new dental restorations and receiving preventive procedures did not differ between groups. CONCLUSION: Continuous use of xerostomic medications can increase the risk for tooth extraction in people with dementia. This study highlights the importance of careful consideration when prescribing xerostomic medications to people with dementia, and the need for regular and ongoing dental care.
Assuntos
Demência/complicações , Salivação/efeitos dos fármacos , Doenças Dentárias/epidemiologia , Doenças Dentárias/etiologia , Xerostomia/induzido quimicamente , Xerostomia/complicações , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Feminino , Humanos , Estudos Longitudinais , Masculino , Polimedicação , Risco , Suécia/epidemiologiaRESUMO
Xerostomia and hyposalivation are debilitating side effects for patients treated with ionizing radiation for head and neck cancer. Despite technological advances, collateral damage to the salivary glands remains a significant problem for patients and severely diminishes their quality of life. During the wound healing process, restoration of junctional contacts is necessary to maintain polarity, structural integrity, and orientation cues for secretion. However, little is known about whether these structural molecules are impacted following radiation damage and more importantly, during tissue restoration. We evaluated changes in adherens junctions and cytoskeletal regulators in an injury model where mice were irradiated with 5 Gy and a restoration model where mice injected postradiation with insulin-like growth factor 1 (IGF1) are capable of restoring salivary function. Using coimmunoprecipitation, there is a decrease in epithelial (E)-cadherin bound to ß-catenin following damage that is restored to untreated levels with IGF1. Via its adaptor proteins, ß-catenin links the cadherins to the cytoskeleton and part of this regulation is mediated through Rho-associated coiled-coil containing kinase (ROCK) signaling. In our radiation model, filamentous (F)-actin organization is fragmented, and there is an induction of ROCK activity. However, a ROCK inhibitor, Y-27632, prevents E-cadherin/ß-catenin dissociation following radiation treatment. These findings illustrate that radiation induces a ROCK-dependent disruption of the cadherin-catenin complex and alters F-actin organization at stages of damage when hyposalivation is observed. Understanding the regulation of these components will be critical in the discovery of therapeutics that have the potential to restore function in polarized epithelium.
Assuntos
Citoesqueleto de Actina/efeitos da radiação , Junções Aderentes/efeitos da radiação , Glândula Parótida/efeitos da radiação , Lesões por Radiação/patologia , Xerostomia/patologia , Citoesqueleto de Actina/efeitos dos fármacos , Citoesqueleto de Actina/metabolismo , Citoesqueleto de Actina/patologia , Junções Aderentes/efeitos dos fármacos , Junções Aderentes/metabolismo , Junções Aderentes/patologia , Animais , Caderinas/metabolismo , Feminino , Fator de Crescimento Insulin-Like I/administração & dosagem , Camundongos , Glândula Parótida/efeitos dos fármacos , Glândula Parótida/metabolismo , Glândula Parótida/patologia , Ligação Proteica , Doses de Radiação , Lesões por Radiação/tratamento farmacológico , Lesões por Radiação/metabolismo , Lesões por Radiação/fisiopatologia , Recuperação de Função Fisiológica , Salivação/efeitos dos fármacos , Salivação/efeitos da radiação , Xerostomia/tratamento farmacológico , Xerostomia/metabolismo , Xerostomia/fisiopatologia , beta Catenina/metabolismo , Quinases Associadas a rho/metabolismoRESUMO
Cholinergic syndrome is an acute adverse reaction associated with irinotecan. Development of cholinergic syndrome can be ameliorated or prevented by administering various anticholinergics, including atropine sulfate or scopolamine butylbromide. Although many of the side effects are transient and non-life-threatening, their onset is painful and can lower a patient's quality of life (QoL). This retrospective study was performed to identify predictive factors of the development of irinotecan-related cholinergic syndrome in order to develop future strategies for improving the QoL of patients undergoing chemotherapy. We enrolled 150 cancer patients who underwent chemotherapy, which included irinotecan, in our outpatient chemotherapy center between October 2014 and January 2017. For regression analysis, variables related to the development of irinotecan-related cholinergic syndrome were extracted from the patient's clinical records. The degree of cholinergic syndrome was classified as follows: grade 0 = not developed; grade 1 = developed but did not require anticholinergic drugs; and grade 2 = developed and required anticholinergic drugs or stopping the chemotherapy due to cholinergic syndrome. Multivariate ordered logistic regression analysis was performed to identify predictive factors for the development of irinotecan-related cholinergic syndrome. Threshold measurements were determined using a receiver operating characteristic analysis (ROC) curve. Significant factors identified for the development of cholinergic syndrome included female sex [odds ratio (OR) 2.183, 95% confidence interval (CI) 1.010-4.717; P = 0.0471] and irinotecan dose (OR 1.014, 95% Cl 1.007-1.021; P = 0.0001). ROC curve analysis of the group likely to develop cholinergic syndrome indicated that the threshold for the irinotecan dose was 175 mg or above (area under the curve = 0.69). In conclusion, female sex and irinotecan dose were identified as significant predictors of the development of cholinergic syndrome.
Assuntos
Dor Abdominal/induzido quimicamente , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Camptotecina/análogos & derivados , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Camptotecina/administração & dosagem , Camptotecina/efeitos adversos , Diarreia/induzido quimicamente , Feminino , Fluoruracila/administração & dosagem , Fluoruracila/efeitos adversos , Humanos , Irinotecano , Leucovorina/administração & dosagem , Leucovorina/efeitos adversos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico , Valor Preditivo dos Testes , Qualidade de Vida , Estudos Retrospectivos , Salivação/efeitos dos fármacos , Síndrome , Adulto JovemRESUMO
BACKGROUND AND OBJECTIVE: Goldenhar syndrome (ocular-auricular-vertebral syndrome), a rare congenital condition arising from defects in the first and second brachial arches, consists in clinical variety of features ranging from facial abnormalities, ear-eye abnormalities, vertebral defects and congenital heart problems and severe obstructive sleep apnea. Due to craniofacial abnormalities, patients presents mechanical obstructive phenomena and sialorrhea that cause prone position, language's fastening, use of nasopharyngeal cannulas and tracheal intubation. METHODS: In this article, we report a case of a 16 years old child affected by Goldenhar syndrome and sialorrhea to demonstrate improvement of the daily patient management, through inoculations of botulinum toxin type A. Due to severe sialorrhea which caused tracheobronchial daily aspirations, the caregivers used an external aspirators. RESULTS: In the first infiltration (August 2016) the parotid and submandibular glands bilaterally were inoculated with incobotulinum toxin type A (Xeomin®, Merz Pharma) with dosages of 5 UI for each of them, for a total of 20 UI without clinical efficacy (no quantitative and qualitative saliva reducing during 3 months). In the second (November 2016) and third (February 2017) infiltrations each parotid and each submandibular glands were injected with a (dosage of 7 UI and 5 UI respectively (total of 24 UI of incobotulinumtoxin A) with important clinical results (saliva production and tracheo-bronchial aspirations reduced). CONCLUSION: Therefore, botulinum toxin type A could be a good and non invasive treatment of sialorrhea in Goldenhar syndrome to improve oral hygiene and daily patient management.
Assuntos
Toxinas Botulínicas Tipo A/administração & dosagem , Síndrome de Goldenhar/complicações , Fármacos Neuromusculares/administração & dosagem , Glândula Parótida/efeitos dos fármacos , Salivação/efeitos dos fármacos , Sialorreia/terapia , Glândula Submandibular/efeitos dos fármacos , Adolescente , Síndrome de Goldenhar/diagnóstico , Humanos , Injeções , Masculino , Glândula Parótida/fisiopatologia , Qualidade de Vida , Recuperação de Função Fisiológica , Índice de Gravidade de Doença , Sialorreia/diagnóstico , Sialorreia/etiologia , Sialorreia/fisiopatologia , Glândula Submandibular/fisiopatologia , Sucção , Resultado do TratamentoRESUMO
OBJECTIVE: Bone marrow cell extract (BMCE) was previously reported to restore salivary gland hypofunction caused by irradiation injury. Proteins were shown to be the main active factors in BMCE. However, BMCE therapy requires multiple injections and protein denaturation is a concern during BMCE storage. This study aimed to preserve, by lyophilization (freeze-drying), the bioactive factors in BMCE. METHODS: We developed a method to freeze-dry BMCE and then to analyze its ingredients and functions in vivo. Freeze-dried (FD) BMCE, freshly prepared BMCE (positive control), or saline (vehicle control) was injected into the tail vein of mice that had received irradiation to damage their salivary glands. RESULTS: Results demonstrated that the presence of angiogenesis-related factors and cytokines in FD-BMCE remained comparable to those found in fresh BMCE. Both fresh and FD-BMCE restored comparably saliva secretion, increased cell proliferation, upregulated regenerative/repair genes, protected salivary acinar cells, parasympathetic nerves, and blood vessels from irradiation-damaged salivary glands. CONCLUSION: Lyophilization of BMCE maintained its bioactivity and therapeutic effect on irradiation-injured salivary glands. The advantages of freeze-drying BMCE are its storage and transport at ambient temperature.
Assuntos
Células da Medula Óssea , Extratos Celulares/farmacologia , Lesões Experimentais por Radiação/tratamento farmacológico , Glândulas Salivares/fisiologia , Salivação/efeitos dos fármacos , Células Acinares/fisiologia , Indutores da Angiogênese/análise , Animais , Extratos Celulares/química , Proliferação de Células/efeitos dos fármacos , Citocinas/análise , Feminino , Liofilização , Camundongos , Neovascularização Fisiológica/efeitos dos fármacos , Glândulas Salivares/citologiaAssuntos
Antígenos de Superfície/química , Glutamato Carboxipeptidase II/química , Neoplasias de Próstata Resistentes à Castração/radioterapia , Neoplasias da Próstata/radioterapia , Lesões por Radiação , Radioisótopos/química , Glândulas Salivares/efeitos da radiação , Humanos , Ligantes , Masculino , Neoplasias da Próstata/diagnóstico por imagem , Neoplasias de Próstata Resistentes à Castração/diagnóstico por imagem , Risco , Saliva/efeitos da radiação , Salivação/efeitos dos fármacos , Resultado do Tratamento , Xerostomia/etiologiaRESUMO
The objective of this study was to assess the oral health status of users of illicit drugs such as marijuana and cocaine/crack and compare it with individuals not using these chemical substances. Questionnaires were applied to 35 illicit drugs users to gather information on demographic status, general health, and use of drugs. Then, a clinical assessment of the oral health condition was performed to collect data on decayed, missing and filled teeth (DMFT) index, salivary flow rate (SFR), and mucosal lesions. The control group was composed of 35 non-illicit drug users. In the experimental group, 91.43% were males, 80% were smokers, and 42.85% were alcoholics. Cocaine was the most common drug used (77.15%), followed by marijuana (68.6%), and crack (51.4%). The average DMFT index was 9.8 and the SFR was reduced in 60% of subjects. Mucosal alterations were detected, but no potentially malignant disorders or oral cancer were diagnosed. Compared to control group, significantly higher values for gender (40%, p = 0.0001), smoking (22.86%) and heavy drinking (5.7%) habits (p = 0.0001), SFR (31.4%; p = 0.0308), and oral lesions (p = 0.0488) were found for the experimental group, although significantly higher values were found in the control group for DMFT index (p = 0.0148). It can be concluded that the use of illicit drugs contributed to an increased prevalence of oral mucosa lesions. In addition, a decline on SFR and a reduced DMFT index was observed for illicit drug users.
Assuntos
Transtornos Relacionados ao Uso de Cocaína/complicações , Abuso de Maconha/complicações , Doenças da Boca/induzido quimicamente , Mucosa Bucal/efeitos dos fármacos , Saúde Bucal/estatística & dados numéricos , Adulto , Idoso , Idoso de 80 Anos ou mais , Alcoolismo/complicações , Alcoolismo/epidemiologia , Estudos de Casos e Controles , Transtornos Relacionados ao Uso de Cocaína/epidemiologia , Estudos Transversais , Índice CPO , Feminino , Humanos , Masculino , Abuso de Maconha/epidemiologia , Pessoa de Meia-Idade , Doenças da Boca/epidemiologia , Fatores de Risco , Salivação/efeitos dos fármacos , Taxa Secretória/efeitos dos fármacos , Distribuição por Sexo , Fumar/efeitos adversos , Fumar/epidemiologia , Fatores Socioeconômicos , Inquéritos e Questionários , Adulto JovemRESUMO
BACKGROUND: Salivary gland dysfunction is an 'umbrella' term for the presence of either xerostomia (subjective sensation of dryness), or salivary gland hypofunction (reduction in saliva production). It is a predictable side effect of radiotherapy to the head and neck region, and is associated with a significant impairment of quality of life. A wide range of pharmacological interventions, with varying mechanisms of action, have been used for the prevention of radiation-induced salivary gland dysfunction. OBJECTIVES: To assess the effects of pharmacological interventions for the prevention of radiation-induced salivary gland dysfunction. SEARCH METHODS: Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 14 September 2016); the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 14 September 2016); MEDLINE Ovid (1946 to 14 September 2016); Embase Ovid (1980 to 14 September 2016); CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1937 to 14 September 2016); LILACS BIREME Virtual Health Library (Latin American and Caribbean Health Science Information database; 1982 to 14 September 2016); Zetoc Conference Proceedings (1993 to 14 September 2016); and OpenGrey (1997 to 14 September 2016). We searched the US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform for ongoing trials. No restrictions were placed on the language or date of publication when searching the electronic databases. SELECTION CRITERIA: We included randomised controlled trials, irrespective of their language of publication or publication status. Trials included participants of all ages, ethnic origin and gender, scheduled to receive radiotherapy on its own or in addition to chemotherapy to the head and neck region. Participants could be outpatients or inpatients. We included trials comparing any pharmacological agent regimen, prescribed prophylactically for salivary gland dysfunction prior to or during radiotherapy, with placebo, no intervention or an alternative pharmacological intervention. Comparisons of radiation techniques were excluded. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 39 studies that randomised 3520 participants; the number of participants analysed varied by outcome and time point. The studies were ordered into 14 separate comparisons with meta-analysis only being possible in three of those.We found low-quality evidence to show that amifostine, when compared to a placebo or no treatment control, might reduce the risk of moderate to severe xerostomia (grade 2 or higher on a 0 to 4 scale) at the end of radiotherapy (risk ratio (RR) 0.35, 95% confidence interval (CI) 0.19 to 0.67; P = 0.001, 3 studies, 119 participants), and up to three months after radiotherapy (RR 0.66, 95% CI 0.48 to 0.92; P = 0.01, 5 studies, 687 participants), but there is insufficient evidence that the effect is sustained up to 12 months after radiotherapy (RR 0.70, 95% CI 0.40 to 1.23; P = 0.21, 7 studies, 682 participants). We found very low-quality evidence that amifostine increased unstimulated salivary flow rate up to 12 months after radiotherapy, both in terms of mg of saliva per 5 minutes (mean difference (MD) 0.32, 95% CI 0.09 to 0.55; P = 0.006, 1 study, 27 participants), and incidence of producing greater than 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; P = 0.004, 1 study, 175 participants). However, there was insufficient evidence to show a difference when looking at stimulated salivary flow rates. There was insufficient (very low-quality) evidence to show that amifostine compromised the effects of cancer treatment when looking at survival measures. There was some very low-quality evidence of a small benefit for amifostine in terms of quality of life (10-point scale) at 12 months after radiotherapy (MD 0.70, 95% CI 0.20 to 1.20; P = 0.006, 1 study, 180 participants), but insufficient evidence at the end of and up to three months postradiotherapy. A further study showed no evidence of a difference at 6, 12, 18 and 24 months postradiotherapy. There was low-quality evidence that amifostine is associated with increases in: vomiting (RR 4.90, 95% CI 2.87 to 8.38; P < 0.00001, 5 studies, 601 participants); hypotension (RR 9.20, 95% CI 2.84 to 29.83; P = 0.0002, 3 studies, 376 participants); nausea (RR 2.60, 95% CI 1.81 to 3.74; P < 0.00001, 4 studies, 556 participants); and allergic response (RR 7.51, 95% CI 1.40 to 40.39; P = 0.02, 3 studies, 524 participants).We found insufficient evidence (that was of very low quality) to determine whether or not pilocarpine performed better or worse than a placebo or no treatment control for the outcomes: xerostomia, salivary flow rate, survival, and quality of life. There was some low-quality evidence that pilocarpine was associated with an increase in sweating (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004, 5 studies, 389 participants).We found insufficient evidence to determine whether or not palifermin performed better or worse than placebo for: xerostomia (low quality); survival (moderate quality); and any adverse effects.There was also insufficient evidence to determine the effects of the following interventions: biperiden plus pilocarpine, Chinese medicines, bethanechol, artificial saliva, selenium, antiseptic mouthrinse, antimicrobial lozenge, polaprezinc, azulene rinse, and Venalot Depot (coumarin plus troxerutin). AUTHORS' CONCLUSIONS: There is some low-quality evidence to suggest that amifostine prevents the feeling of dry mouth in people receiving radiotherapy to the head and neck (with or without chemotherapy) in the short- (end of radiotherapy) to medium-term (three months postradiotherapy). However, it is less clear whether or not this effect is sustained to 12 months postradiotherapy. The benefits of amifostine should be weighed against its high cost and side effects. There was insufficient evidence to show that any other intervention is beneficial.
Assuntos
Radioterapia/efeitos adversos , Doenças das Glândulas Salivares/prevenção & controle , Xerostomia/prevenção & controle , Amifostina/uso terapêutico , Medicamentos de Ervas Chinesas/uso terapêutico , Feminino , Fator 7 de Crescimento de Fibroblastos/uso terapêutico , Humanos , Masculino , Pilocarpina/uso terapêutico , Qualidade de Vida , Protetores contra Radiação/efeitos adversos , Protetores contra Radiação/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Saliva Artificial , Doenças das Glândulas Salivares/etiologia , Glândulas Salivares/efeitos da radiação , Salivação/efeitos dos fármacos , Salivação/efeitos da radiação , Xerostomia/etiologiaRESUMO
BACKGROUND: Breast cancer is one of the most common cancers in India. Most of the patients with breast cancer are treated with chemotherapy which has multiple oral complications. AIMS: The objectives of this study were to describe the occurrence of taste disturbances, xerostomia, oral mucositis, oral pigmentation, and candidal and salivary changes among patients receiving chemotherapy for breast cancer. METHODS: Fifty-two women with newly diagnosed breast cancer (without distant metastasis), eligible for adjuvant/neoadjuvant chemotherapy (cyclophosphamide and adriamycin, 4 cycles × 3 weeks), were included in this study. All the observations were noted before, during (after 6 weeks of starting chemotherapy), and after the completion of chemotherapy (after 12 weeks of starting chemotherapy). STATISTICAL ANALYSIS USED: Variables such as mucositis, salivary flow rate, salivary pH, and candidal carriage rate were compared at baseline, and at 1st and 2nd follow-ups using Wilcoxon signed-rank test (P value corrected for α for pair-wise comparisons). RESULTS: Mean unstimulated whole salivary flow rate reduced from 0.5 ml/min to 0.3 ml/min, and the mean colony-forming units of Candida reduced from 32.3 × 103 cells/ml to 13.1 × 103 cells/ml at the end of the study period. Xerostomia, taste disturbances, and oral mucosal pigmentation increased from 28.8% to 50%. CONCLUSIONS: There was a discernible change in oral mucosal, salivary, and candidal status during the course of the study.